Tarsus Pharmaceuticals Inc. (TARS): Price and Financial Metrics

Tarsus Pharmaceuticals Inc. (TARS): $15.87

-0.57 (-3.47%)

POWR Rating

Component Grades













Add TARS to Watchlist
Sign Up

Industry: Biotech



in industry


  • TARS scores best on the Sentiment dimension, with a Sentiment rank ahead of 64% of US stocks.
  • The strongest trend for TARS is in Value, which has been heading down over the past 26 weeks.
  • TARS ranks lowest in Momentum; there it ranks in the 5th percentile.

TARS Stock Summary

  • TARS's price/sales ratio is 27.33; that's higher than the P/S ratio of 95.25% of US stocks.
  • Over the past twelve months, TARS has reported earnings growth of 494.34%, putting it ahead of 96.48% of US stocks in our set.
  • Revenue growth over the past 12 months for TARSUS PHARMACEUTICALS INC comes in at -71.5%, a number that bests merely 2.34% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to TARSUS PHARMACEUTICALS INC are ENTX, VLDR, SDGR, PSNL, and DYAI.
  • Visit TARS's SEC page to see the company's official filings. To visit the company's web site, go to www.tarsusrx.com.

TARS Valuation Summary

  • TARS's price/sales ratio is 27.6; this is 475% higher than that of the median Healthcare stock.
  • TARS's price/earnings ratio has moved up 45.9 over the prior 26 months.

Below are key valuation metrics over time for TARS.

Stock Date P/S P/B P/E EV/EBIT
TARS 2022-12-05 27.6 2.2 -7.0 -4.8
TARS 2022-12-02 28.7 2.3 -7.3 -5.1
TARS 2022-12-01 27.9 2.2 -7.1 -4.8
TARS 2022-11-30 27.8 2.2 -7.1 -4.8
TARS 2022-11-29 27.2 2.2 -6.9 -4.7
TARS 2022-11-28 27.6 2.2 -7.0 -4.8

TARS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TARS has a Quality Grade of B, ranking ahead of 79.3% of graded US stocks.
  • TARS's asset turnover comes in at 0.335 -- ranking 138th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows TARS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.335 0.963 -0.432

TARS Price Target

For more insight on analysts targets of TARS, see our TARS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $53.80 Average Broker Recommendation 1.1 (Strong Buy)

TARS Stock Price Chart Interactive Chart >

Price chart for TARS

TARS Price/Volume Stats

Current price $15.87 52-week high $26.95
Prev. close $16.44 52-week low $10.80
Day low $15.39 Volume 91,500
Day high $16.67 Avg. volume 113,692
50-day MA $17.13 Dividend yield N/A
200-day MA $16.19 Market Cap 423.28M

Tarsus Pharmaceuticals Inc. (TARS) Company Bio

Tarsus is a clinical-stage biopharmaceutical company headquartered in Irvine, California. Tarsus was founded in 2017 to bring innovative therapies to a range of diseases in need of better solutions, starting with Demodex blepharitis and eye care.

TARS Latest News Stream

Event/Time News Detail
Loading, please wait...

TARS Latest Social Stream

Loading social stream, please wait...

View Full TARS Social Stream

Latest TARS News From Around the Web

Below are the latest news stories about TARSUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate TARS as an investment opportunity.

Tarsus Pharmaceuticals GAAP EPS of -$0.84 misses by $0.12

  • Tarsus Pharmaceuticals press release (NASDAQ:TARS): Q3 GAAP EPS of -$0.84 misses by $0.12.
  • As of September 30, 2022, cash, cash equivalents and marketable securities were $226.6M.
  • Cash runway anticipated into at least 2026 for the planned commercial launch of TP-03 and continued pipeline development.

Seeking Alpha | November 11, 2022

Tarsus Pharmaceuticals Third Quarter 2022 Earnings: US$0.84 loss per share (vs US$0.76 loss in 3Q 2021)

Tarsus Pharmaceuticals ( NASDAQ:TARS ) Third Quarter 2022 Results Key Financial Results Net loss: US$22.5m (loss...

Yahoo | November 11, 2022

Tarsus Pharmaceuticals GAAP EPS of -$0.84 beats by $0.13

Tarsus Pharmaceuticals press release (TARS): Q3 GAAP EPS of -$0.84 beats by $0.13.As of September 30, 2022, cash, cash equivalents and marketable securities were $226.6 million

Seeking Alpha | November 9, 2022

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Misses Revenue Estimates

Tarsus Pharmaceuticals, Inc. (TARS) delivered earnings and revenue surprises of 14.29% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 9, 2022

Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements

New Drug Application for TP-03 accepted; PDUFA target action date August 25, 2023 Launched disease education, field medical team and payor engagement in anticipation of TP-03 launch Cash runway anticipated into at least 2026 for the planned commercial launch of TP-03 and continued pipeline development IRVINE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to address patient needs, starting with eye care, through the application of proven s

Yahoo | November 9, 2022

Read More 'TARS' Stories Here

TARS Price Returns

1-mo -12.03%
3-mo -1.43%
6-mo 20.50%
1-year -35.88%
3-year N/A
5-year N/A
YTD -29.47%
2021 -45.56%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6428 seconds.